Literature DB >> 12805059

The recurrent IgH translocations are highly associated with nonhyperdiploid variant multiple myeloma.

Rafael Fonseca1, Carina S Debes-Marun, Elisa B Picken, Gordon W Dewald, Sandra C Bryant, Jerry M Winkler, Emily Blood, Martin M Oken, Rafael Santana-Dávila, Natalia González-Paz, Robert A Kyle, Morie A Gertz, Angela Dispenzieri, Martha Q Lacy, Philip R Greipp.   

Abstract

Aneuploid is ubiquitous in multiple myeloma (MM), and 4 cytogenetic subcategories are recognized: hypodiploid (associated with a shorter survival), pseudodiploid, hyperdiploid, and near-tetraploid MM. The hypodiploid, pseudodiploid, and near-tetraploid karyotypes can be referred to as the nonhyperdiploid MM. Immunoglobulin heavy-chain (IgH) translocations are seen in 60% of patients. We studied the relation between aneuploidy and IgH translocations in MM. Eighty patients with MM and abnormal metaphases were studied by means of interphase fluorescent in situ hybridization (FISH) to detect IgH translocations. We also studied a second cohort of 199 patients (Eastern Cooperative Oncology Group [ECOG]) for IgH translocations, chromosome 13 monosomy/deletions (Delta13), and ploidy by DNA content. Mayo Clinic patients with abnormal karyotypes and FISH-detected IgH translocation were more likely to be nonhyperdiploid (89% versus 39%, P <.0001). Remarkably, 88% of tested patients with hypodiploidy (16 of 18) and 90% of tested patients with tetraploidy (9 of 10) had an IgH translocation. ECOG patients with IgH translocations were more likely to have nonhyperdiploid MM by DNA content (68% versus 21%, P <.001). This association was seen predominantly in patients with recurrent chromosome partners to the IgH translocation (11q13, 4p16, and 16q23). The classification of MM into hyperdiploidy and nonhyperdiploidy is dictated largely by the recurrent (primary) IgH translocations in the latter.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12805059     DOI: 10.1182/blood-2003-02-0493

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  75 in total

1.  Monosomy 13 in metaphase spreads is a predictor of poor long-term outcome after bortezomib plus dexamethasone treatment for relapsed/refractory multiple myeloma.

Authors:  Miki Kiyota; Tsutomu Kobayashi; Shinichi Fuchida; Mio Yamamoto-Sugitani; Muneo Ohshiro; Yuji Shimura; Shinsuke Mizutani; Hisao Nagoshi; Nana Sasaki; Ryuko Nakayama; Yoshiaki Chinen; Natsumi Sakamoto; Hitoji Uchiyama; Yosuke Matsumoto; Shigeo Horiike; Chihiro Shimazaki; Junya Kuroda; Masafumi Taniwaki
Journal:  Int J Hematol       Date:  2012-03-17       Impact factor: 2.490

Review 2.  Microarray-based understanding of normal and malignant plasma cells.

Authors:  John De Vos; Dirk Hose; Thierry Rème; Karin Tarte; Jérôme Moreaux; Karéne Mahtouk; Michel Jourdan; Hartmut Goldschmidt; Jean-François Rossi; Friedrich W Cremer; Bernard Klein
Journal:  Immunol Rev       Date:  2006-04       Impact factor: 12.988

3.  The clinical significance of cereblon expression in multiple myeloma.

Authors:  Steven R Schuster; K Martin Kortuem; Yuan Xiao Zhu; Esteban Braggio; Chang-Xin Shi; Laura A Bruins; Jessica E Schmidt; Greg Ahmann; Shaji Kumar; S Vincent Rajkumar; Joseph Mikhael; Betsy Laplant; Mia D Champion; Kristina Laumann; Bart Barlogie; Rafael Fonseca; P Leif Bergsagel; Martha Lacy; A Keith Stewart
Journal:  Leuk Res       Date:  2013-09-05       Impact factor: 3.156

4.  Establishment and exploitation of hyperdiploid and non-hyperdiploid human myeloma cell lines.

Authors:  Xin Li; Angela Pennisi; Fenghuang Zhan; Jeffrey R Sawyer; John D Shaughnessy; Shmuel Yaccoby
Journal:  Br J Haematol       Date:  2007-09       Impact factor: 6.998

5.  Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma.

Authors:  P Leif Bergsagel; W Michael Kuehl; Fenghuang Zhan; Jeffrey Sawyer; Bart Barlogie; John Shaughnessy
Journal:  Blood       Date:  2005-03-08       Impact factor: 22.113

Review 6.  Molecular pathogenesis of multiple myeloma: basic and clinical updates.

Authors:  Marta Chesi; P Leif Bergsagel
Journal:  Int J Hematol       Date:  2013-02-28       Impact factor: 2.490

7.  Secondary genomic rearrangements involving immunoglobulin or MYC loci show similar prevalences in hyperdiploid and nonhyperdiploid myeloma tumors.

Authors:  Ana Gabrea; Maria Luisa Martelli; Ying Qi; Anna Roschke; Bart Barlogie; John D Shaughnessy; Jeffrey R Sawyer; W Michael Kuehl
Journal:  Genes Chromosomes Cancer       Date:  2008-07       Impact factor: 5.006

8.  Translocation t(11;14) and survival of patients with light chain (AL) amyloidosis.

Authors:  Alan H Bryce; Rhett P Ketterling; Morie A Gertz; Martha Lacy; Ryan A Knudson; Steven Zeldenrust; Shaji Kumar; Suzanne Hayman; Francis Buadi; Robert A Kyle; Philip R Greipp; John A Lust; Stephen Russell; S Vincent Rajkumar; Rafael Fonseca; Angela Dispenzieri
Journal:  Haematologica       Date:  2009-02-11       Impact factor: 9.941

9.  A rare case of acute lymphoblastic leukemia in a patient with light chain (AL) amyloidosis treated with lenalidomide.

Authors:  Ranjit Nair; Shereen Gheith; Dan Popescu; Nicole M Agostino
Journal:  Int J Clin Exp Pathol       Date:  2014-04-15

10.  c-Met signaling promotes IL-6-induced myeloma cell proliferation.

Authors:  Håkon Hov; Erming Tian; Toril Holien; Randi Utne Holt; Thea K Våtsveen; Unn-Merete Fagerli; Anders Waage; Magne Børset; Anders Sundan
Journal:  Eur J Haematol       Date:  2009-01-06       Impact factor: 2.997

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.